IL1RL2 and neoplasm: Such facts indicate that when adopting IL-36 cytokines as immunotherapeutic materials, it should be carefully considered the expression levels of IL-36R as well as IL-1RAcP on tumor cells and whether IL-36/IL-36R/IL-1RAcP can significantly promote tumor growth.